• 1
    American Cancer Society. California Facts and Figures 2006. Oakland, CA: California Division and Public Health Institute, California Cancer Registry; 2005.
  • 2
    Campleman S, Curtis R. Demographic aspects of breast cancer incidence and mortality in California, 1988–1999. In: MorrisC, KwongSL, eds. Breast Cancer in California, 2003 Sacramento, CA: California Department of Health Services, Cancer Surveillance Section, July 2004.
  • 3
    Chu KC, Lamar CA, Freeman HP. Racial disparities in breast carcinoma survival rates: separating factors that affect diagnosis from factors that affect treatment. Cancer. 2003; 97: 28532860.
  • 4
    Polite BN, Olopade OI. Breast cancer and race: a rising tide does not lift all boats equally. Perspect Biol Med. 2005; 48(1 Suppl ): S166175.
  • 5
    Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 2005; 97: 439448.
  • 6
    Cunningham JE, Butler WM. Racial disparities in female breast cancer in South Carolina: clinical evidence for a biological basis. Breast Cancer Res Treat. 2004; 88: 161176.
  • 7
    Newman LA. Breast cancer in African-American women. Oncologist. 2005; 10: 114.
  • 8
    Ries L, Eisner M, Kosary M. SEER Cancer Statistics Review, 1975–2000. Bethesda, MD: National Cancer Institute, 2003.
  • 9
    Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747752.
  • 10
    Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100: 84188423.
  • 11
    Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98: 1086910874.
  • 12
    Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003; 95: 14821485.
  • 13
    Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006; 19: 264271.
  • 14
    Kandel MJ, Stadler Z, Masciari S, et al. Prevalence of BRCA1 mutations in triple negative breast cancer (BC). J Clin Oncol (Meeting Abstracts). 2006; 24(18 Suppl ): 508.
  • 15
    Cancer Reporting in California: Abstracting and Coding Procedures for Hospitals. California Cancer Reporting System Standards. Vol. I. Sacramento, CA: California Department of Health Services, Cancer Surveillance Section, 2006.
  • 16
    Fritz AG. International classification of diseases for oncology: ICD-O. 3rd ed. Geneva: World Health Organization; 2000.
  • 17
    Fritz A. Recording tumor markers in collaborative staging system site-specific factors. Available from URL: Accessed April on 28, 2006.
  • 18
    DAKO HERCEPTest Information Web site. Summary of Procedure, Vol. 2006, October 15, 2003. Available from URL: Accessed on June 7, 2006.
  • 19
    PathVysion. HER-2 DNA probe kit package insert. Vysis, Downers Grove, CA, February, 2002.
  • 20
    Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control. 2001; 12: 703711.
  • 21
    Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002.
  • 22
    SEER Extent of Disease 1998, Codes and Coding Instructions. 3rd ed. Bethesda, MD: National Cancer Institute, National Institutes of Health; 1998.
  • 23
    Seiffert JE, National Cancer Institute (U.S.). SEER Program: Comparative Staging Guide for Cancer. Bethesda, MD: U.S. Dept. of Health and Human Services Public Health Service National Institutes of Health National Cancer Institute, 1993.
  • 24
    Fleiss JL, Levin BA, Paik MC. Statistical Methods for Rates and Proportions. 3rd ed. Hoboken, NJ: Wiley-Interscience; 2003.
  • 25
    Ayanian JZ, Kohler BA, Abe T, Epstein AM. The relation between health insurance coverage and clinical outcomes among women with breast cancer. N Engl J Med. 1993; 329: 326331.
  • 26
    Breen N, Wesley MN, Merrill RM, Johnson K. The relationship of socio-economic status and access to minimum expected therapy among female breast cancer patients in the National Cancer Institute Black-White Cancer Survival Study. Ethn Dis. 1999; 9: 111.
  • 27
    McWhorter WP, Mayer WJ. Black/white differences in type of initial breast cancer treatment and implications for survival. Am J Public Health. 1987; 77: 15151517.
  • 28
    Bradley CJ, Given CW, Roberts C. Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst. 2002; 94: 490496.
  • 29
    Gordon NH. Socioeconomic factors and breast cancer in black and white Americans. Cancer Metastasis Rev. 2003; 22: 5565.
  • 30
    Field TS, Buist DS, Doubeni C, et al. Disparities and survival among breast cancer patients. J Natl Cancer Inst Monogr. 2005: 8895.
  • 31
    Jatoi I, Becher H, Leake CR. Widening disparity in survival between white and African-American patients with breast carcinoma treated in the U. S. Department of Defense Healthcare system. Cancer. 2003; 98: 894899.
  • 32
    Wojcik BE, Spinks MK, Optenberg SA. Breast carcinoma survival analysis for African American and white women in an equal-access health care system. Cancer. 1998; 82: 13101318.
  • 33
    Albain KS, Unger J, Hutchins LF. Outcome of African Americans on Southwest Oncology Group (SWOG) breast cancer adjuvant therapy trials. San Antonio Breast Cancer Symposium 2003: 21.
  • 34
    Joslyn SA, West MM. Racial differences in breast carcinoma survival. Cancer. 2000; 88: 114123.
  • 35
    Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, Colditz GA. Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol. 2006; 24: 13421349.
  • 36
    Newman LA, Mason J, Cote D, et al. African-American ethnicity, socioeconomic status, and breast cancer survival: a meta-analysis of 14 studies involving over 10,000 African-American and 40,000 white American patients with carcinoma of the breast. Cancer. 2002; 94: 28442854.
  • 37
    Aziz H, Hussain F, Sohn C, et al. Early onset of breast carcinoma in African American women with poor prognostic factors. Am J Clin Oncol. 1999; 22: 436440.
  • 38
    Furberg H, Millikan R, Dressler L, Newman B, Geradts J. Tumor characteristics in African American and white women. Breast Cancer Res Treat. 2001; 68: 3343.
  • 39
    Henson DE, Chu KC, Levine PH. Histologic grade, stage, and survival in breast carcinoma: comparison of African American and Caucasian women. Cancer. 2003; 98: 908917.
  • 40
    Jones BA, Kasl SV, Howe CL, et al. African-American/white differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer. 2004; 101: 12931301.
  • 41
    Newman LA, Alfonso AE. Age-related differences in breast cancer stage at diagnosis between black and white patients in an urban community hospital. Ann Surg Oncol. 1997; 4: 655662.
  • 42
    Shavers VL, Harlan LC, Stevens JL. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer. 2003; 97: 134147.
  • 43
    Carey LA, Perou CM, Dressler LG, et al. Race and the poor prognosis basal breast tumor (BBT) phenotype in the population-based Carolina Breast Cancer Study (CBCS). J Clin Oncol (Meeting Abstracts). 2004; 22(14 Suppl ): 9510.
  • 44
    Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295: 24922502.
  • 45
    Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004; 10: 53675374.
  • 46
    Rodriguez-Pinilla SM, Sarrio D, Honrado E, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res. 2006; 12: 15331539.